Provided by Tiger Trade Technology Pte. Ltd.

Ashland

59.23
-0.5450-0.91%
Volume:353.47K
Turnover:21.00M
Market Cap:2.71B
PE:-3.22
High:60.86
Open:60.86
Low:58.75
Close:59.77
52wk High:74.57
52wk Low:45.21
Shares:45.76M
Float Shares:41.77M
Volume Ratio:0.48
T/O Rate:0.85%
Dividend:1.64
Dividend Rate:2.77%
EPS(TTM):-18.3696
EPS(LYR):-18.3696
ROE:-34.45%
ROA:2.05%
PB:1.42
PE(LYR):-3.22

Loading ...

Mizuho Securities Adjusts Ashland Price Target to $70 From $60, Maintains Outperform Rating

MT Newswires Live
·
Yesterday

U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar

Reuters
·
Yesterday

Ashland Shares Rise After BMO Capital Upgrade

MT Newswires Live
·
Dec 16

Ashland Seen Benefiting From Restructuring, Activist Push -- Market Talk

Dow Jones
·
Dec 16

BMO Capital Upgrades Ashland to Outperform From Market Perform, Adjusts PT to $71 From $61

MT Newswires Live
·
Dec 15

Ashland Inc : Bmo Raises to Outperform From Market Perform; Raises Target Price to $71 From $61

THOMSON REUTERS
·
Dec 15

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

GlobeNewswire
·
Dec 12

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

GlobeNewswire
·
Dec 11

Stock Market Navigation_Dec 10, 2025_Announcements and Trading Tips for Shanghai and Shenzhen Markets

Deep News
·
Dec 10

Financial Morning Brief: Solar Industry Braces for Fourth Restructuring as First-Tier Cities See 4-Year High in Secondary Home Sales | Dec 10, 2025

Deep News
·
Dec 10

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Benzinga_recent_news
·
Dec 10

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

GlobeNewswire
·
Dec 09

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

GlobeNewswire
·
Dec 09

LEADS BIOLABS-B (09887) Rises Over 3% as Breakthrough Data for LBL-034 Presented at 2025 ASH Annual Meeting

Stock News
·
Dec 09

Terns Pharmaceuticals (TERN): Evaluating Rich Valuation After CARDINAL Trial Update and 2025 ASH Presentation

Simply Wall St.
·
Dec 09

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

GlobeNewswire
·
Dec 09

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

GlobeNewswire
·
Dec 09

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

GlobeNewswire
·
Dec 09

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

GlobeNewswire
·
Dec 09

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

GlobeNewswire
·
Dec 09